uPAR: A versatile signalling orchestrator

Nature Reviews Molecular Cell Biology

Volumn 3, Issue 12, 2002, Pages 932-943

  Blasi, Francesco ^a   Carmeliet, Peter ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN; CELL RECEPTOR; G PROTEIN COUPLED RECEPTOR; INTEGRIN; PROTEIN KINASE; UROKINASE RECEPTOR;

ANGIOGENESIS; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL ADHESION; CELL DIFFERENTIATION; CELL DIVISION; CELL MOVEMENT; GENE TARGETING; HUMANS; INTEGRINS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATORS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036906177     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrm977     Document Type: Review

References (126)

1. Collen, D. The plasminogen (fibrinolytic) system. Thromb. Haemost. 82, 259-270 (1999).
2. Appella, E. et al. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J. Biol. Chem, 262, 4437-4440 (1987).
3. Ploug, M. & Ellis, V. Structure-function relationship in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom a-neurotoxins. FEBS Lett, 349, 163-168 (1994).
4. Behrendt, N, Roenne, E. & Danoe, K. Domain interplay in the urokinase receptor-requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites In distinct receptor domains. J. Biol. Chem. 271, 22885-22894 (1996).
5. Ploug, M. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry 37, 16494-16505 (1998).
6. Waltz, D. A. & Chapman, H. A. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 269, 14746-14750 (1994).
7. Loskutoff, D. J., Curriden, S. A., Hu, G. & Deng, G. Regulation of cell adhesion by PAI-1. APMIS. 107, 54-61 (1999).
8. Nykjær, A. et al. Purified a2-macroglobulin receptor/LDL receptor-related protein binds urokinase-plasminogen activator inhibitor type-1 complex. Evidence that the a2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes, J. Biol. Chem. 267, 14543-14546 (1992).
9. Czekay, R. P., Kuemmel, T. A., Orlando, R. A. & Farquhar M. G. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity, Mol. Biol. Cell 12, 1467-1479 (2001).
10. Nykjær, A. et al. Recycling of the urokinase receptor during internalization of the uPA-serpin complexes. EMBO J. 16, 2610-2620 (1997).
11. Sidenius, N., Andolfo, A., Fesce, R. & Blasi, F. Urokinase regulates vitronectin binding in vitro and in vivo by controlling urokinase receptor oligomerization. J. Biol. Chem. 277, 27982-27990 (2002).
12. Resnati, M. et al. Proteolytic cleavage of the urokinase, receptor substitutes for the agonist-induced chemotactic effect, EMBO J. 15, 1572-1582 (1996).
13. Giancotti, F. G. & Ruoslahti, E. Integrin signaling. Science 285, 1028-1032 (1999).
14. Wei, Y. et al. Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555 (1996). This paper discusses a molecular basis for the mechanism by which uPAR can regulate signalling, by showing a direct interaction between uPAR and integrins.
15. Yebra, M. et al. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration. J. Biol. Chem. 271, 29393-29399 (1996).
16. Degryse, B., Orlando, S., Resnati, M., Rabbani, S. A. & Blasi, F. Urokinase/urokinase receptor and vitronectin/avb3 integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 20, 2032-2043 (2001).
17. May, A. E. et al. Urokinase receptor (CD87) regulates leukocyte recruitment via β2 integrins in vivo. J. Exp. Med. 188, 1029-1037 (1998). This paper reports a role of uPAR as a signalling receptor in leukocyte recruitment.
18. Waltz, D. A. et al. Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am. J. Respir. Cell Mol. Biol. 22, 316-322 (2000).
19. Bohuslav, J. et al. Urokinase plasminogen activator receptor. β2-integrins, and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181, 1381-1390 (1995).
20. Aguirre Ghiso, J. A., Kovalski, K. & Ossowski, L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104 (1999).
21. Carriero, M. V. et al Urokinase receptor interacts with α(v)β5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 59, 5307-5314 (1999).
22. Tarui, T., Mazar, A. P., Cines, D. B. & Takada, Y. Urokinase receptor (uPAR/CD87) is a ligand for integrin and mediates cell-cell interaction. J. Biol. Chem. 276, 3983-3990 (2000).
23. Simon, D. I. et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J. Biol. Chem. 275, 10226-10234 (2000).
24. Wei, Y., Eble, J. A., Wang, Z., Kreidberg, J. A. & Chapman, H. A. Urokinase receptor promotes b1 integrin function through interactions with integrin a3b1. Mol. Biol. Cell 12, 2975-2986 (2001).
25. Liu, D., Aguirre-Ghiso, J. A., Estrada, Y. & Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457 (2002).
26. Montuori, N., Camero, M. V., Salzano, S., Rossi, G. & Ragno, P. The cleavage of the urokinase receptor regulates its multiple functions. J. Biol. Chem. 2002 Sep 23 (DOI: 10.10744/jbc.M207494200).
27. Fazioli, F. et al. The urokinase-sensitive region of the urokinase receptor is responsible for its potent chemotactic activity EMBO J. 16, 7279-7286 (1997). This paper identifies the chemotactic epitope of uPAR.
28. Degryse, B. et al. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis, and cytoskeleton reorganization in rat smooth muscle cells via the urokinase receptor. Blood 94, 649-662 (1999).
29. Nguyen, D. H. et al. Urokinase-type plasminogen activator stimulates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J. Biol. Chem. 275, 19382-19388 (2000).
30. Resnati, M. et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA 99, 1359-1364 (2002). This study reports the interaction of uPAR with GPCR.
31. Le, Y. et al. A New Insight in the Role of Old Chemotactic Peptide Receptor FPR and FPRL1: Down-Regulation opf Chemokine Receptors CCR5 and CXCR4 Forum 94, 299-311 (1999).
32. Simons, K. & Toomre, D. Lipid rafts and signal transduction. Nature Rev. Mol. Cell Biol. 1, 31-39 (2000).
33. Wei, Y., Yang, X., Lu, Q., Wilkins, J. A. & Chapman, H. A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 144, 1285-129 (1999).
34. Gomez-Mouton, C. et al. Segregation of leading-edge and uropod components into specific lipid rafts during T cell polarization, Proc. Natl. Acad. Sci. USA 98, 9642-9647 (2001). This paper shows the existence of two types of glycophospholipid raft (containing GM1 or GM3), and the segregation of uPAR with chemokine receptors in GM3 rafts that are present specifically at the leading edge of a migrating lymphocyte.
35. Koshelnick, Y., Ehart, M., Hufnagl, P., Heinrich, P. C. & Binder B. R. Urokinase receptor is associated with the components of the JAK:STAT1 signaling pathway and leads to the activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272, 28563-28567 (1997).
36. Weaver, A. M., Hussaini, I. M., Mazar, A., Henkin, J. & Gonias, S. L. Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin. J. Biol. Chem. 272, 14372-14379 (1997).
37. Webb, D. J., Nguyen, D. H., Sankovic, M. & Gonias, S. L. The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J. Biol. Chem 274, 7412-7420 (1999).
38. Degryse, B., Sier, C. F. M., Resnati. M., Conese, M. & Blasi, F. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett. 505, 249-254 (2001).
39. Nykjaer, A et al. Mannose-6-phosphate/insulin like growth factor II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J. Cell Biol. 141, 815-828 (1998).
40. Behrendt, N. et al. A urokinase receptor-associated protein with specific collagen binding properties. J. Biol. Chem. 275, 1993-2002 (2000).
41. Aguirre-Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K. & Ossowski, L. Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38 (MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12, 863-879 (2001). This paper identifies the integrin as the target of uPAR in uPAR-dependent cell proliferation, and the requirement of this interaction for cell growth.
42. Webb, D. J., Nguyen, D. H. & Gonias, S. L. Extracellular signal-regulated kinase functions in the urokinase receptor dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and Matrigel invasion. J. Cell Sci. 113, 123-134 (2000).
43. Kjoeller, L. & Hall, A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152, 1145-1157 (2001).
44. Nguyen, D. H. et al. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J. Cell Biol. 146, 149-164 (1999).
45. Busso, N., Masur, S. K., Lazega, D., Waxman, S. & Ossowski, L. Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126, 259-270 (1994).
46. Myohanen, H. T. et al. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J. Histochem. Cytochem. 41, 1291-1301 (1993).
47. Sitrin, R. G., Pan, P. M., Harper, H. A., Blackwood, R. A. & Todd, R. F. Urokinase receptor (CD87) aggregation triggers phosphoinositide hydrolysis and intracellular calcium mobilization in mononuclear phagocytes. J. Immunol. 163, 6193-6200 (1999).
48. Sitrin, R. G., Pan, P. M., Blackwood, R. A., Huang, J. & Petty, H. R. Evidence for a signaling partnership between urokinase receptors (cd87) and I-selectin (cd621) in human polymorphonuclear neutrophils. J. Immunol. 166, 4822-4825(2001).
49. Le, Y et al. Amyloid (β)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J. Neurosci. 21, RC123 (2001).
50. Dumler, L. et al. The JAK/STAT pathway and urokinase receptor signaling in human aortin vascular smooth muscle cells. J. Biol. Chem. 273, 315-321 (1998).
51. Wang, N, Planus, E., Pouchelet, M., Fredberg, J. J. & Badovatz-Meimon, G. Urokinase receptor mediates mechanical force transfer across the cell surface. Am. J. Physiol. 268, C1062-C1066 (1995).
52. Kusch, A. et al. Urokinase stimulates human vascular smooth muscle cells migration via a phosphatidylinositol 3-kinase-tyk2 interaction. J. Biol. Chem. 275, 39466-39473 (2000).
53. Sidenius, N. & Blasi, F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett. 470, 40-46 (2000).
54. Stepanova, V. et al. Urokinase-dependent human vascular smooth muscle cells adhesion requires selective vitronectin phorphorylation by ecto-protein kinase CK2. J. Biol. Chem. 277, 10266-10272 (2002).
55. Simon, D. I. et al. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 88, 3185-3194 (1996).
56. Nusrat, A. R. & Chapman, H. A. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J. Clin. Invest. 87, 1091-1097 (1991).
57. Ferias-Eisner, R. et al. Thye urokinase plasminogen activator receptor (uPAR) is preferentially induced by nerve growth factors in PC12 pheomocromocytoma cells and is required for NGF-driven differentiation. J. Neurosci. 20, 230-239 (2000).
58. Rabbani, S. A. et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J. Biol. Chem. 267, 14151-14156 (1992).
59. Kirchheimer, J. C., Wojta, J., Christ, G., Hienert, G. & Binder, B. R. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J. 1, 125-128 (1987).
60. Yu, W., Kim, J. & Ossowski, L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J. Cell Biol. 137, 767-777 (1997).
61. Carmeliet, P. et al. Receptor-independent role of urokinasetype plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J. Cell Biol. 140, 233-245 (1998). This paper provides a possible explanation for the redundant role of uPAR as protease receptor, in part because uPA binds other ECM components.
62. Chiaradonna, F. et al. Urokinase receptor-dependent and -independent p56/59hck activation state is a molecular switch between myelomonocytic cell motility and adherence. EMBO J. 11, 3013-3023 (1999).
63. Kook, Y. H., Adamski, J., Zelent, A. & Ossowski, L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 13, 3983-3991 (1994).
64. Luttun, A., Dewerchin, M., Collen, D. & Carmellet, P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: Insights from genetic studies. Curr. Atheroscler. Rep. 2, 407-416 (2000).
65. Degen, J. L. Genetic interactions between the coagulation and fibrinolytic systems. Thromb. Haemost. 86, 130-137 (2001).
66. Eitzman, D. T. & Ginsburg, D. Of mice and men. The function of plasminogen activator inhibitors (PAls) in vivo. Adv. Exp. Med. Biol. 425, 131-141 (1997).
67. Carmeliet, P. et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 369, 419-424 (1994). The first study of a proteinase knockout in mice, reporting the crucial role of tPA and uPA in normal health.
68. Bugge, T. H. et al. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 270, 16886-16894 (1995). This paper reports the normal phenotype of uPARdeficient mice.
69. Dewerchin, M. et al. Generation and characterization of urokinase receptor-deficient mice. J. Clin. Invest. 97, 870-878 (1996). This paper reports the normal phenotype of uPAR-deficient mice.
70. Ploplis, V. A. et al. Effects of disruption of the plasminogen gene on thrombosis, growth and health in mice. Circulation 92, 2586-2593 (1995).
71. Bugge, T. H., Flick, M. J., Daugherty, C. C. & Degen, J. L. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9, 794-807 (1995).
72. Bugge, T. H. et al. Loss of fibrinogen rescues mice from pleiotropic effects of plasminogen deficiency., Cell 87, 709-719 (1996).
73. Bugge, T. H. et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA 93, 5899-5904 (1996). This study reports that uPAR is redundant as a protease receptor in fibrin surveillance.
74. Carmeliet, P. & Collen, D. Development and disease in proteinase-deficient mice: Role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb. Res. 91,255-285 (1998).
75. Carmeliet, P. et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nature Genet. 17, 439-444 (1997). This paper reports that matrix metalloproteinases are activated by uPA-generated plasmin in vivo.
76. Moons, L. et al. Reduced transplant arteriosclerosis in plasminogen-deficient mice. J. Clin. Invest. 102, 1788-1797 (1998).
77. Carmeliet, P. et al. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Clin. Res. 81, 829-839 (1997).
78. Heymans, S. et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Med. 5, 1135-1142 (1999). This paper reports that loss of uPA, but not uPAR, prevents destruction of the ischaemic myocardium, thereby showing a redundant role of uPAR as a proteinase receptor.
79. Lund, L. R. et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 18, 4645-4656 (1999).
80. Romer, J. et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med. 2, 287-292 (1996).
81. Bajou, K. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med. 4, 923-928 (1998).
82. Bajou, K. et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol. 152, 777-784 (2001). This paper reports a redundant role of host uPAR in tumour vascularization.
83. Carmeliet, P., Moons, L., Ploplis, V., Plow, E. & Collen, D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99, 200-208 (1997).
84. Levi, M. et al. Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. Circulation 103, 2014-2020 (2001).
85. Soriano, S. G. et al. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke 30, 134-139 (1999).
86. Gyetko, M. R. et al. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J. Immunol. 165, 1513-1519 (2000). This paper reports a role of uPAR as a signalling receptor in neutrophil recruitment.
87. Metzler, B. et al. Mouse model of myocardial remodelling after ischemia: Role of intercellular adhesion molecule-1. Cardiovasc. Res. 49, 399-407 (2001).
88. Bunting, M., Harris, E. S., McIntyre, T. M., Prescott, S. M. & Zimmerman, G. A. Leukocyte adhesion deficiency syndromes: Adhesion and tethering defects involving β2 integrins and selectin ligands. Curr. Opin. Hematol. 9, 30-35 (2002).
89. Gyetko, M. R. et al. Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA. J. Immunol. 167, 5539-5542 (2001).
90. Gyetko, M. R., Todd, R. F., Wilkinson, C. C. & Sitrin, R. G. The urokinase receptor is required for human monocyte chemotaxis in vitro. J. Clin. Invest. 93, 1380-1387 (1994).
91. Rijneveld, A. W. et al. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J. Immunol 168, 3507-3511 (2002).
92. Gyetko, M. at al. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J. Clin. Invest. 97, 1818-1826 (1996).
93. Jones, S. P. et al. Leukocyte and endothelial cell adhesion molecules in a chronic murine model of myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 279, 196-201 (2000).
94. Alfano, M., Sidenius, N., Panzeri, B., Blasi, F. & Poli, G. Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc. Natl. Acad. Sci. USA 99, 8862-8867 (2002).
95. Speth, C., Pichler, I., Stockl, G., Mair, M. & Dierich, M. P. Urokinase plasminogen activator receptor (uPAR; CD87) expression on monocytic cells and T cells is modulated by HIV-1 infection. Immunobiology 199, 152-162 (1998).
96. Coleman, J. L., Gebbia J. A. & Benach J. L. Borrelia burgdorfen and other bacterial products induce expression and release of the urokinase receptor. J. Immunol. 166, 473-480 (2001).
97. Sidenius, N. et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96, 4091-4095 (2000).
98. Florquin, S. et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int. 59, 2054-2061 (2001).
99. Xue, W., Hashimoto, K. & Toi, Y. Functional involvement of urokinase-type plasminogen activator receptor in pemphigus acantholysis. J. Cutan Pathol. 25, 469-474 (1998).
100. Del Rosso, M., Fibbi, G. & Matucci Cerinic, M. The urokinase-type plasminogen activator system and inflammatory joint diseases. Clin. Exp. Rheumatol. 17, 485-498 (1999).
101. Walker, D. G., Lue, L. F. & Beach, T. G. Increased expression of the urokinase plasminogen-activator receptor in amyloid β peptide-treated human brain microglia and in AD brains. Brain Res. 926, 69-79 (2002).
102. Okada, S. S. et al. Native atherosclerosis and vein graft arterialization: Association with increased urokinase receptor expression in vitro and in vivo. Thromb. Haemost. 80, 140-147 (1998).
103. Solberg, H., Ploug, M., Hoyer-Hansen, G., Nielsen, B, S. & Lund, L. R. The murine receptor of urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J. Histochem. Cytochem. 49, 237-246 (2001).
104. Bisgaard, H. C., Santoni-Rugiu, E., Nagy, P. & Thorgeirsson, S. S. Modulation of the plasminogen activator/plasmin system in rat liver regenerating by recruitment of oval cells. Lab. Invest. 78, 237-246 (1998).
105. Stephens, R. W. et al. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J. Natl. Cancer Inst. 91, 869-874 (1999). This paper shows that, in colon carcinoma patients, high serum levels of uPAR predict poor survival.
106. Crowley, C. W. et al. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA 90, 5021-5025 (1993). In a human xenografted tumour model, co-expression of inhibitors of the uPA-uPAR interaction block metastasis.
107. Min, H. Y. et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 56, 2428-2433 (1996). Interference with the uPA-uPAR interaction blocks tumour angiogenesis and growth.
108. Stoppelli, M. P. et al. Autocrine saturation of pro-urokinase receptor on human A431 cells. Cell 45, 675-684 (1986).
109. Pyke, C. et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinoma. Am. J. Pathol. 138, 1059-1067 (1991).
110. Brunner, N. et al. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS, 107, 160-167 (1999).
111. Lakka, S. S. et al. Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines. Clin. Cancer Res, 7, 1087-1093 (2001).
112. Ploug, M. et al. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40, 12157-12168 (2001).
113. Pepper, M. S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21, 1104-1117 (2001).
114. Carmeliet, P. & Jain, R, K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
115. Jain, R. K. & Carmeliet, R. K. Vessels of death or life. Sci. Am. 285, 38-45 (2001).
116. Thewes, M., Eisner, E., Wessner, D., Engst, R. & Ring, J. The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study. Int. J. Dermatol, 39, 188-191 (2000).
117. Fibbi, G. et al. Urokinase-dependent angiogenesis in vitro and diacyglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab. Invest. 78, 1109-1119 (1998).
118. Li, H. et al. Adenovirus mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther. 5, 1105-1113 (1998).
119. Harbeck, N. et al. Clinical relevance of the plasminogen activator inhibitor type 1 - A multifaceted proteolytic factor. Onkolegie 24, 238-244 (2001).
120. Lambert, V. et al. Influence of plasminogen activator inhibitor type-1 on choroidal neovascularization. FASEB J. 15, 1021-1027 (2001).
121. Gutierrez, L. S. et al. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 60, 5839-5847 (2000).
122. McMahon, G. A. et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 276, 33964-33968 (2001).
123. Stefansson, S. et al. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J. Biol. Chem. 276, 8135-8141 (2001).
124. Devy, L. et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 16, 147-154 (2002).
125. Ossowski, L. & Aguirre Ghiso, J. A. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12, 613-620 (2000). A thoughtful survey of the signalling pathways that are activated by uPAR.
126. Carmeliet, P. & Collen, D. Transgenic mouse models in angiogenesis and cardiovascular disease. J. Pathol. 190, 387-405 (2000).